Practicability and Acceptability of Stylomax® in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00476385
Recruitment Status : Completed
First Posted : May 22, 2007
Last Update Posted : February 12, 2009
Information provided by:

Brief Summary:

Primary objective:

to evaluate the practicability and acceptability of STYLOMAX®, a new injection device for MAXOMAT®, in children, for 1 year.

Condition or disease Intervention/treatment Phase
Growth Hormone Deficiency Drug: somatropine Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Usability and Acceptability of Stylomax® in Growth Hormone Deficient Children.
Study Start Date : June 2003
Actual Primary Completion Date : December 2005

Arm Intervention/treatment
Experimental: somatropine Drug: somatropine
subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg

Primary Outcome Measures :
  1. practicability/acceptability of the Stylomax pen [ Time Frame: at each visit ]

Secondary Outcome Measures :
  1. tolerability : pain (evaluation on pain scale) [ Time Frame: at each visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children over 3 years of age with growth hormone deficiency, requiring treatment with MAXOMAT® according to the criteria of the MA.

Exclusion Criteria:

  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00476385

Paris, France
Sponsors and Collaborators
Study Director: Marie SEBILLE, Dr Sanofi

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00476385     History of Changes
Other Study ID Numbers: L_8912
First Posted: May 22, 2007    Key Record Dates
Last Update Posted: February 12, 2009
Last Verified: February 2009

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases